Proceedings · Session S-184 · filed November 17, 2026
Corporate & Industrial R&DSession paper
Argenx to Buy Unnatural Products for Up to $1.15B in Peptide Push
Argenx will pay $550M upfront plus up to $595M in milestones for UNP, gaining a macrocyclic peptide platform targeting historically undruggable disease drivers.
By Priya Raman5 min read992 words
Summary
- Argenx agreed to acquire UNP for $550M upfront plus up to $595M in milestones, totaling up to $1.15B.
- Vyvgart franchise sales hit $4.534B in the first nine months of 2026, up 58% year over year.
- The deal follows Argenx's up to $2.2B acquisition of Forte Biosciences completed August 27.
- Argenx halted the Phase III UNITY Sjögren's trial October 8 after an IDMC futility recommendation.
- The FDA requested October 23 an additional confirmatory trial for efgartigimod SC in dermatomyositis.

Argenx has agreed to acquire Unnatural Products (UNP) for $550 million in upfront cash plus up to $595 million in development and regulatory milestones, a deal worth up to $1.15 billion that converts the immunology company from a minority stakeholder into sole owner of the Santa Cruz-based macrocyclic peptide discovery firm.
The announcement marks Argenx's second planned acquisition in under four months, following its up to $2.2 billion buyout of Forte Biosciences completed on August 27. Both deals aim to diversify Argenx beyond its antibody-based portfolio, which is anchored by the blockbuster Vyvgart franchise. The boards of both companies have approved the transaction, which is expected to close by year's end subject to customary conditions.
"Our ambition is to be the leading immunology innovation company, and as Argenx builds its next chapter, we are investing with discipline where it will count the most for patients," Argenx CEO Karen Massey said in a statement.
Why does Argenx want macrocyclic peptides?
The acquisition builds on a collaboration launched in July 2025 to develop oral macrocyclic peptides against multiple historically "undruggable" targets. UNP's platform combines AI-guided compound design, massively parallel synthesis and direct-to-biology screening. Under the original agreement, UNP conducted research through IND-enabling studies, with Argenx holding an exclusive option to develop and commercialize products across multiple indications.
"What the platform's about is being able to take smart shots on goal" in order to "find a successful hypothesis to weave your way through that chemical landscape to a development candidate," UNP CEO and co-founder Cameron Pye, PhD, told GEN.
The strategic logic is modalities that biologics cannot easily deliver: oral or long-acting treatments for serious immune-mediated diseases. Argenx's marketed portfolio consists of Vyvgart (efgartigimod alfa-fcab) injection for adults with generalized myasthenia gravis (gMG), and Vyvgart Hytrulo, a subcutaneous combination of the FcRn inhibitor with hyaluronidase indicated for gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).
That franchise generated $4.534 billion in net product sales during the first nine months of 2026, up 58% from $2.866 billion in the same period a year earlier. Third-quarter sales reached $1.721 billion, up 53% from $1.127 billion in Q3 2025.
How did investors and analysts respond?
Argenx shares on Euronext Brussels rose nearly 5% on Monday, from €815.80 ($906.11) to €853.80 ($948.23). Its Nasdaq-listed American depositary shares climbed nearly 4%, from $927.21 to $962.27. On Tuesday, the Brussels shares inched up another 1% to €863.40 ($958.89) by 11:01 am ET, while ADSs rose 0.21% to $964.27 by 11:15 am ET.
The modest bounce appeared to reflect lingering investor skittishness after two setbacks in the past month. On October 8, Argenx shares fell more than 10% after the company ended the Phase III UNITY trial (NCT06684847) of subcutaneous efgartigimod in moderate-to-severe Sjögren's disease, following the Independent Data Monitoring Committee's recommendation to stop for futility after concluding the study would not meet its primary endpoint.
Then on October 23, the FDA requested an additional confirmatory registrational trial for efgartigimod SC in dermatomyositis. The agency reasoned that while the Phase II/III ALKIVIA trial (NCT05523167) showed positive overall results, the dermatomyositis patient subgroup was too small to achieve statistical significance.
In contrast to the market's hesitation, Leerink Partners' Thomas J. Smith, senior managing director of immunology and metabolism, backed the deal. "We like this deal for ARGX as it brings engineering and design capabilities to generate macrocyclic peptides (i.e., oral, long-acting, etc.), signaling confidence in oral FcRn potential and expanding on the company's early-stage pipeline with potential for further modalities beyond specialized antibodies," Smith wrote Monday. He added that the deal "represents potential for longer-term strategic value given both I&I and large pharma's focus on oral and long-acting therapeutics capable of driving enhanced efficacy with improved convenience vs. conventional biologics."
What does UNP bring to the table?
Pye and Joshua Schwochert, PhD, founded UNP in 2016 in a garage on the west side of Santa Cruz, California, during their final year of doctoral research in the lab of Scott Lokey, PhD, at the University of California, Santa Cruz. Lokey's group studies how stereochemistry and N-methylation patterns govern cell permeability, and applies that relationship to create diverse, permeable drug scaffolds with the selectivity that constrained peptides can offer.
UNP raised $32 million in a Series A financing completed in 2023, led by Merck Global Health Innovation Fund and TechBio-focused ARTIS Ventures. Beyond Argenx, its biopharma partners include:
- Novartis — up to $1.8 billion, including $100 million upfront, launched in February for an undisclosed cardiovascular program.
- Merck & Co. — undisclosed upfront with up to $220 million in milestones, launched in 2024 against an oncology target.
- BridgeBio Pharma — undisclosed value, launched in 2024 for rare diseases and oncology.
The companies have not disclosed progress toward development candidates under the Argenx collaboration. Following closing, UNP's staff and leadership will continue operating from Santa Cruz, which will serve as Argenx's hub for peptide discovery. UNP will lead discovery work within a strategic framework agreed with Argenx, which brings clinical development and commercialization capabilities.
"Today is a tremendous milestone for UNP and a testament to the exceptional work of our scientists, employees, collaborators and supporters," Pye stated. "From the earliest days, we believed our platform had the potential to redefine what is possible in the discovery and design of new medicines." Massey added that after working together for more than two years, "we also know there is a strong fit in how we work: science first, entrepreneurial and focused on patients."
With both boards aligned and closing expected before the end of the year, Argenx will enter 2027 owning a peptide discovery engine positioned to extend its FcRn-led immunology franchise into oral and long-acting territory.
via clinicaltrials.gov (Original)
Filed under
- argenx
- unnatural-products
- macrocyclic-peptides
- ai-drug-discovery
- corporate-acquisitions
More from Priya Raman
Show full bio
Staff writer covering money, funding and market shifts around research and development at Hypothesis Wire.
281 articles
References
- AI accountability, FDA shifts and a $1.15 billion deal
- Argenx posts rare Phase 3 miss as Vyvgart fails in Sjögren's disease
- Sanofi Pays $1 Billion Upfront to Extend Regeneron Antibody Alliance
- Novartis Pays $575M Upfront for Chinese mRNA Autoimmune Asset
- Novartis Bets $7.8 Billion on Abogen's RNA Platform for Autoimmune Disease